- Trial phase
- Preclinical / IND-enabling, Phase 1 trial authorized (EU CTIS) but not yet recruiting
- Time to market
- Unknown, still in preclinical/IND-enabling stage with Phase 1 trial authorized but not recruiting; likely 5-7+ years from potential approval if successful
- Why 2/10
- NX-3911 has no hard, dated binary catalyst in the next ~12 months. The Phase 1 trial is authorized in the EU (CTIS2026-526014-87-00) but not yet recruiting. Even when Phase 1 data read out, this is a partnered program with Sanofi (not Nurix's lead asset), so the stock impact is indirect and diluted. NRIX's main value drivers are the bexobrutideg/Roche deal and its wholly-owned pipeline.
NX-3911 is a minor, partnered pipeline component for NRIX. Investors should focus on the company's wholly-owned BTK degrader bexobrutideg (partnered with Roche, $700M upfront) and other pipeline catalysts for stock movement. NX-3911 specific news (Phase 1 initiation or early data) would likely drive only modest, indirect moves via milestone optics.
Price Chart
Executive Summary
NX-3911 is an oral STAT6 degrader being developed by Nurix Therapeutics (NRIX) in collaboration with Sanofi for Type 2 inflammatory diseases (atopic dermatitis, asthma). Sanofi licensed the program in June 2025 for $15M upfront, with up to $465M in milestones. The drug is still in preclinical/IND-enabling stages; a Phase 1 EU trial is authorized but not recruiting. NX-3911 is a minor pipeline component for NRIX, which recently signed a transformative $700M upfront deal with Roche for its lead BTK degrader bexobrutideg. NX-3911 faces significant competition from Kymera's KT-621 (already in Phase 2b) and Recludix/Sanofi's REX-8756 (Phase 1). For NRIX investors, this drug is a long-dated, partnered option, not a near-term catalyst.
How It Works
NX-3911 is an oral (pill) drug that uses targeted protein degradation to destroy a protein called STAT6 inside cells. STAT6 is a key signaling molecule in allergic and inflammatory conditions like atopic dermatitis (eczema) and asthma. By degrading STAT6, the drug aims to shut down the inflammation-driving pathway at its source. This is a degrader approach (destroy the protein) rather than a traditional inhibitor (block the protein).
Trial Status
NX-3911 advanced into IND-enabling studies after Sanofi exercised a license extension option in June 2025. An EU-authorized Phase 1 trial (CTIS2026-526014-87-00, sponsored by Sanofi) was registered but recruitment has not yet started as of mid-2026. The drug is still described as "preclinical stage" in company materials from May/June 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 trial initiation (EU CTIS trial CTIS2026-526014-87-00), recruitment start date unknown
- Potential early Phase 1 data readout (no date announced)
- Sanofi milestone payments triggered by development progress
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report